【摘要】 目的:分析比较肿瘤患者和健康人外周血CD4~+CD25~+调节性T细胞的特点,为肿瘤免疫学研究及治疗探索新方法。方法:收集并分离30例肿瘤患者和32例健康人的外周血单个核细胞(PBMCs),用荧光标记的抗人CD4及抗人CD25单抗标记肿瘤患者和健康人PBMCs细胞,FCM检测CD4~+CD25~+Treg细胞,分析CD4~+CD25~+Treg细胞在肿瘤患者和健康人中的差别。结果:肿瘤患者的CD4~+CD25~+Treg细胞百分数明显高于健康人(年龄<55者62.4 vs 40.4;年龄≥55者53.1 vs 31.0,P<0.05)。结论:肿瘤患者的CD4~+CD25~+Treg细胞高于健康对照,为肿瘤免疫治疗提供新策略,通过删除CD4~+CD25~+Treg细胞,有可能增强抗瘤免疫反应。更多还原

【Abstract】 Objective:The alteration of CD4~+ CD25 ~+ T regulatory lymphocytes(CD4 ~+ CD25 ~+ Treg cells) subpopulation in peripheral blood mononuclear cells(PBMCs) from patients with cancer was analyzed,and to explore a new strategy for tumor immunity and tumor immunotherapy.Methods:Peripheral blood mononuclear cells(PBMCs) from 30 cases of various cancer patients and 32 healthy controls were collected.PBMCs of patients and health controls were stained by PE anti - human CD4 antibody and FITC anti - human CD25 antibody.The frequency of CD4 ~+ CD25 ~+ Treg cells was identified by flow cytometry,and the CD4~+ CD25~+ Treg cells of patients with cancer compared with healthy controls.Results:The results showed that the CD4 ~+ CD25 ~+ Treg cells from patients with cancer were significantly higher than that of healthy controls(aged<55 62.4 vs 40.4;aged≥55 53.1 vs 31.0,P<0.05).Conclusion: The CD4 ~+ CD25 ~+ Treg cells from patients with cancer were higher than that of healthy controls,the results provide a new basis for the design of future tumor immunotherapeutic strategies.To neutralize CD4 ~+ CD25 ~+ Treg in patients with cancer will enhance the efficacy of anticancer immunizations.更多还原